FDA Approved Drugs for Otolaryngology (Ear, Nose, Throat)

Drugs Approved in 2015

Otiprio (ciprofloxacin otic suspension); Otonomy; For the treatment of pediatrics with bilateral otitis media with effusion undergoing tympanostomy tube placement, Approved December 2015

Drugs Approved in 2014

Grastek (Timothy Grass Pollen Allergen Extract); Merck; For the treatment of grass pollen-induced allergic rhinitis, Approved April 2014

Oralair (Sweet Vernal, Orchard, Perennial Rye, Timothy and Kentucky Blue Grass Mixed Pollens Allergen Extract); Greer Labs; For the treatment of grass pollen-induced allergic rhinitis with or without conjunctivitis, Approved April 2014

Ragwitek (Short Ragweed Pollen Allergen Extract); Merck; For the treatment of short ragweed pollen-induced allergic rhinitis, Approved April 2014

Xtoro (finafloxacin otic suspension) 0.3%; Alcon; For the treatment of acute otitis externa, Approved December 2014

Drugs Approved in 2012

Dymista (azelastine hydrochloride and fluticasone propionate); Meda Pharmaceuticals Inc; For the relief of symptoms of seasonal allergic rhinitis, Approved May 2012

Qnasl (beclomethasone dipropionate) nasal aerosol; Teva Pharmaceutical; For the treatment of seasonal and perennial allergic rhinitis, Approved March 2012

Drugs Approved in 2011

Vandetanib (vandetanib); AstraZeneca; For the treatment of thyroid cancer, Approved April 2011

Drugs Approved in 2010

Oravig (miconazole); Strativa Pharmaceuticals; oropharyngeal candidiasis, Approved April 2010

Drugs Approved in 2008

Astepro (azelastine hydrochloride nasal spray); Meda Pharmaceuticals Inc; For the treatment of seasonal and perennial allergic rhinitis, Approved October 2008

Moxatag (amoxicillin); MiddleBrooke Pharmaceuticals; For the treatment of tonsillitis and/or pharyngitis secondary to Streptococcus pyogenes in adults and pediatrics, Approved January 2008

Patanase (olopatadine hydrochloride); Alcon; For the treatment of seasonal allergic rhinitis, Approved April 2008

Drugs Approved in 2007

Veramyst (fluticasone furoate); GlaxoSmithKline; For the treatment of seasonal and perennial allergic rhinitis, Approved April 2007

Xyzal (levocetirizine dihydrochloride); UCB; For the treatment of seasonal and perennial allergic rhinitis and urticaria, Approved May 2007

Drugs Approved in 2000

Depakote ER (divalproex sodium); Abbott Laboratories; For the prophylaxis (prevention) of migraine headaches in adults, Approved August 2000

Protonix (pantoprazole sodium) Delayed-Release Tablets; Wyeth; For treatment of erosive esophagitis, Approved February 2000

Tri-Nasal Spray (triamcinolone acetonide spray); Muro Pharmaceutical; For treatment of nasal symptoms of allergic rhinitis in adults and children age 12 or older, Approved February 2000

Drugs Approved in 1999

Ethyol (amifostine); US Bioscience, Alza; Treatment for xerostomia (dry mouth) due to radiation, Approved June 1999

Drugs Approved in 1998

Rocephin; Roche; Treatment for pediatric otitis media, Approved January 1998

Drugs Approved in 1997

Floxin otic; Daiichi Sankyo; Treatment for otitis media, Approved December 1997

Omnicef; Warner-Lambert; Treatment against various bacterias, Approved December 1997

Drugs Approved in 1996

Bactroban Nasal 2% (mupirocin calcium ointment); SmithKline Beecham; Treatment for nasal bacteria, Approved April 1996

Drugs Approved in 1995

Cedax (ceftibuten); Schering-Plough; Treatment for chronic bronchitis, acute bacterial otitis media, pharyngitis/tonsillitis, Approved December 1995